S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
Free Trial
OTCMKTS:PPCB

Propanc Biopharma (PPCB) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free PPCB Stock Alerts
$0.0013
0.00 (-7.14%)
(As of 05:18 PM ET)
Compare
Today's Range
$0.0013
▼
$0.0016
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.26
Volume
5.62 million shs
Average Volume
3.23 million shs
Market Capitalization
$67,795.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest
PPCB stock logo

About Propanc Biopharma Stock (OTCMKTS:PPCB)

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

PPCB Stock Price History

PPCB Stock News Headlines

April 16, 2024 | finance.yahoo.com
Propanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office
April 10, 2024 | stockhouse.com
Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
April 16, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
April 8, 2024 | finance.yahoo.com
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
February 22, 2024 | finance.yahoo.com
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study
January 16, 2024 | finance.yahoo.com
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
December 18, 2023 | finance.yahoo.com
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
December 13, 2023 | finance.yahoo.com
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
April 16, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
December 12, 2023 | finance.yahoo.com
James Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDaily
November 7, 2023 | finanznachrichten.de
Propanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
November 7, 2023 | finance.yahoo.com
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
August 15, 2023 | finance.yahoo.com
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
July 26, 2023 | finance.yahoo.com
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
July 13, 2023 | finance.yahoo.com
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
July 5, 2023 | finance.yahoo.com
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
June 30, 2023 | sg.finance.yahoo.com
PPCB - Propanc Biopharma, Inc.
June 28, 2023 | finance.yahoo.com
PROPANC BIOPHARMA INC (PPCB) stock forecast and price target
May 25, 2023 | finance.yahoo.com
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
May 23, 2023 | finance.yahoo.com
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
May 23, 2023 | finance.yahoo.com
Propanc Biopharma Announces Reverse Stock Split
March 28, 2023 | finance.yahoo.com
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
March 16, 2023 | finance.yahoo.com
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
March 14, 2023 | benzinga.com
Xeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, Predictions
February 23, 2023 | seekingalpha.com
PPCB Propanc Biopharma, Inc.
January 11, 2023 | finance.yahoo.com
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
December 17, 2022 | finanznachrichten.de
Propanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
See More Headlines
Receive PPCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/16/2024
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:PPCB
CUSIP
N/A
CIK
1517681
Web
www.propanc.com
Phone
(139) 882-0780
Fax
61 03 9882 9969
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,660,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-1,592.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.06
Quick Ratio
0.06

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.52) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
52,150,000
Free Float
51,206,000
Market Cap
$73,010.00
Optionable
Not Optionable
Beta
1.74
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. James Nathanielsz (Age 50)
    Executive Chairman, CEO, CFO, Treasurer & Secretary
    Comp: $430.28k
  • Dr. Julian Norman Kenyon ChB (Age 76)
    M.D., MB, Chief Scientific Officer, CTO & Director
    Comp: $35.99k
  • Prof. Klaus Kutz
    Chief Medical Officer & Member of Scientific Advisory Board

Key Competitors

View All Competitors

PPCB Stock Analysis - Frequently Asked Questions

How have PPCB shares performed in 2024?

Propanc Biopharma's stock was trading at $0.0120 at the beginning of 2024. Since then, PPCB stock has decreased by 88.3% and is now trading at $0.0014.
View the best growth stocks for 2024 here.

How were Propanc Biopharma's earnings last quarter?

Propanc Biopharma, Inc. (OTCMKTS:PPCB) issued its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.03) earnings per share for the quarter.

When did Propanc Biopharma's stock split?

Shares of Propanc Biopharma reverse split on the morning of Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF).

How do I buy shares of Propanc Biopharma?

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PPCB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
1970’s computer coder issues shocking A.I. warning
TradeSmith
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
You won't believe what Citigroup just did to it's depositors
American Alternative
Options trading has suddenly become more reliable.
Eagle Publishing